LUYE PHARMA Subsidiary Completes Issuance of 1.5 Million Exchangeable Preferred Shares

Deep News12-15

LUYE PHARMA (02186) announced that on December 12, 2025, the issuance of exchangeable preferred shares was completed in accordance with the terms of the subscription agreement. The issuer, Luye Geneora Holding Limited (a wholly-owned subsidiary of the company), has allotted and issued 1.5 million exchangeable preferred shares to the subscribers.

These exchangeable preferred shares can be exchanged for existing shares of Boan Biotechnology held by the group and do not involve the issuance of any new shares by Boan Biotechnology. Based on the initial exchange price of HKD 11.718, the maximum number of Boan Biotechnology shares deliverable upon full exchange of all preferred shares is 100,486,431, representing approximately 16.15% of Boan Biotechnology’s total issued shares as of the announcement date.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment